Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Dendritic cell–intrinsic LKB1-AMPK/SIK signaling controls metabolic homeostasis by limiting the hepatic Th17 response during obesity
Hendrik J.P. vanderZande, Eline C. Brombacher, Joost M. Lambooij, Leonard R. Pelgrom, Anna Zawistowska-Deniziak, Thiago A. Patente, Graham A. Heieis, Frank Otto, Arifa Ozir-Fazalalikhan, Maria Yazdanbakhsh, Bart Everts, Bruno Guigas
Hendrik J.P. vanderZande, Eline C. Brombacher, Joost M. Lambooij, Leonard R. Pelgrom, Anna Zawistowska-Deniziak, Thiago A. Patente, Graham A. Heieis, Frank Otto, Arifa Ozir-Fazalalikhan, Maria Yazdanbakhsh, Bart Everts, Bruno Guigas
View: Text | PDF
Research Article Immunology Metabolism

Dendritic cell–intrinsic LKB1-AMPK/SIK signaling controls metabolic homeostasis by limiting the hepatic Th17 response during obesity

  • Text
  • PDF
Abstract

Obesity-associated metabolic inflammation drives the development of insulin resistance and type 2 diabetes, notably through modulating innate and adaptive immune cells in metabolic organs. The nutrient sensor liver kinase B1 (LKB1) has recently been shown to control cellular metabolism and T cell priming functions of DCs. Here, we report that hepatic DCs from high-fat diet–fed (HFD-fed) obese mice display increased LKB1 phosphorylation and that LKB1 deficiency in DCs (CD11cΔLKB1) worsened HFD-driven hepatic steatosis and impaired glucose homeostasis. Loss of LKB1 in DCs was associated with increased expression of Th17-polarizing cytokines and accumulation of hepatic IL-17A+ Th cells in HFD-fed mice. Importantly, IL-17A neutralization rescued metabolic perturbations in HFD-fed CD11cΔLKB1 mice. Mechanistically, deficiency of the canonical LKB1 target AMPK in HFD-fed CD11cΔAMPKα1 mice recapitulated neither the hepatic Th17 phenotype nor the disrupted metabolic homeostasis, suggesting the involvement of other and/or additional LKB1 downstream effectors. We indeed provide evidence that the control of Th17 responses by DCs via LKB1 is actually dependent on both AMPKα1 and salt-inducible kinase signaling. Altogether, our data reveal a key role for LKB1 signaling in DCs in protection against obesity-induced metabolic dysfunctions by limiting hepatic Th17 responses.

Authors

Hendrik J.P. vanderZande, Eline C. Brombacher, Joost M. Lambooij, Leonard R. Pelgrom, Anna Zawistowska-Deniziak, Thiago A. Patente, Graham A. Heieis, Frank Otto, Arifa Ozir-Fazalalikhan, Maria Yazdanbakhsh, Bart Everts, Bruno Guigas

×

Figure 5

LKB1 deficiency in DCs increases a Th17 response, which is mediated via its downstream targets AMPK and SIK.

Options: View larger image (or click on image) Download as PowerPoint
LKB1 deficiency in DCs increases a Th17 response, which is mediated via ...
(A–C) CD11cWT (black symbols) and CD11cΔLKB1 (open symbols) mice were s.c. injected with Flt3L-secreting B16 melanomas to expand the DC pool. After 10 days, hepatic cDC2s were sorted by FACS for DC phenotyping (A). Expression of indicated DC markers was measured by flow cytometry (B). Expression of indicated genes was measured by qPCR after ex vivo overnight LPS stimulation (C). (D and E) GM-CSF cultured BM-derived DCs (GMDCs) from CD11cWT (WT) mice and CD11cΔAMPK (AMPK KO) mice were first treated with inhibitors targeting LKB1 downstream targets or DMSO for 2 hours before LPS stimulation in the presence of Brefeldin A for 4 additional hours, and compared with CD11cΔLKB1 GMDCs (LKB1 KO). Pro–IL-1β–, IL-6–, IL-23p19–, and LAP-expressing GMDCs were quantified by intracellular cytokine staining/flow cytometry and normalized to WT-DMSO. (F–H) GMDCs (CD11cWT, CD11cΔLKB1, or CD11cΔAMPKα1) were treated with DMSO or SIK-inhibitor for 2 hours and stimulated with OVA and LPS for 24 hours, before being injected into the hock of WT mice. After 8 days, draining popliteal lymph nodes were harvested and RORγt+ and IL-17A+ Th17 cells were evaluated by flow cytometry. Data are expressed as mean ± SEM. Statistical analyses were performed using unpaired t tests (B and C) or 1-way ANOVA followed by Dunnett’s post hoc tests (E–H). *P < 0.05 versus LKB1 KO (n = 9–10 mice per group for A–C; n = 3–6 biological replicates per group for E and n = 4 biological replicates per group for G and H).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts